Pharmacokinetic Considerations for Digoxin in Older People

被引:50
作者
Currie, Geoffrey M. [1 ,2 ,3 ]
Wheat, Janelle M. [1 ,2 ,3 ]
Kiat, Hosen [1 ,2 ,3 ]
机构
[1] Charles Sturt Univ, Fac Sci, Locked Bag 588, Wagga Wagga, NSW 2678, Australia
[2] Macquarie Univ, Australian Sch Adv Med, Cardiac Hlth Inst, Sydney, NSW, Australia
[3] Charles Sturt Univ, Ctr Res Complex Syst, Wagga Wagga, NSW, Australia
来源
OPEN CARDIOVASCULAR MEDICINE JOURNAL | 2011年 / 5卷
关键词
Ageing; digoxin; pharmacokinetics; toxicity;
D O I
10.2174/1874192401105010130
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This review aims to arm readers with a deep understanding of pharmacokinetics of digoxin. Data Sources: Pharmacology and pharmacokinetic references texts, and peer reviewed medical journal manuscripts indexed on Medline included based on currency, accuracy and appropriateness. Results: Physiologic changes and disease associated with aging have an impact on pharmacokinetics and pharmacodynamics of medications. Altered drug response and increased adverse reactions are common amongst the elderly. The narrow therapeutic index of digoxin and pharmacokinetic changes associated with aging increases the risk of toxicity. In the aging population, a number of factors combine to increase the risk, severity and likelihood of hospitalisation or death due to adverse drug effects: changes to absorption, distribution, metabolism and excretion, increased susceptibility to drug sensitivity, co-existing pathology, polypharmacy. Conclusion: A thorough understanding of digoxin pharmacokinetics in the older person is essential for improved therapeutic outcomes, improved compliance, reduced morbidity and improved quality of life.
引用
收藏
页码:130 / 135
页数:6
相关论文
共 32 条
[1]  
Aronow W S, 2000, Heart Dis, V2, P151
[2]   ADVERSE DRUG-REACTIONS - AN OVERVIEW OF SPECIAL CONSIDERATIONS IN THE MANAGEMENT OF THE ELDERLY PATIENT [J].
BRAWN, LA ;
CASTLEDEN, CM .
DRUG SAFETY, 1990, 5 (06) :421-435
[3]  
Bryant B, 2007, PHARM HLTH PROFESSIO
[4]  
CUSACK B, 1979, CLIN PHARMACOL THER, V25, P772
[5]  
Cusack Barry J, 2004, Am J Geriatr Pharmacother, V2, P274, DOI 10.1016/j.amjopharm.2004.12.005
[6]  
Delafuente Jeffrey C, 2008, Consult Pharm, V23, P324, DOI 10.4140/TCP.n.2008.324
[7]   HEPATIC DRUG-METABOLISM AND AGING [J].
DURNAS, C ;
LOI, CM ;
CUSACK, BJ .
CLINICAL PHARMACOKINETICS, 1990, 19 (05) :359-389
[8]  
ElDesoky Ehab S, 2007, Am J Ther, V14, P488, DOI 10.1097/01.mjt.0000183719.84390.4d
[9]  
Ewing AB, 2002, MED ELDERLY
[10]   DIGOXIN METABOLISM IN ELDERLY [J].
EWY, GA ;
KAPADIA, GG ;
YAO, L ;
LULLIN, M ;
MARCUS, FI .
CIRCULATION, 1969, 39 (04) :449-+